Sinaptica…homma etenee; Linkedin
We are thrilled to announce that Sinaptica Therapeutics has been selected for the prestigious MedTech Innovator 2025 Accelerator Cohort, among the top 4% chosen from nearly 1,500 global applicants.
In addition, Sinaptica is one of less than 10 companies selected participate in the Heart and Brain Health Accelerator, in collaboration with American Heart Association Ventures and the AHA Center for Health Technology and Innovation (CHTI).
Our team is honored to participate in this highly competitive program. This opportunity will provide us with unparalleled access to industry leaders, investors, healthcare providers, strategics, and foundations, along with additional mentorship through the AHA specialty track.
This honor helps accelerate our mission to revolutionize #Alzheimers treatment through precision #neuromodulation and recognizes the potential impact of our approach for millions of patients.
A heartfelt thank you to MedTech Innovator (MTI) for this incredible opportunity. We look forward to collaborating with fellow innovators during MTI’s flagship four-month program, and presenting at The MedTech Conference, October 5-8 in San Diego.
#MedTechInnovator #MedTech2025 #InnovationInHealthcare